Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
Andrew R MelvilleMd Yuzaiful Md YusofJohn FittonLeticia Garcia-MontoyaLynda BaileyShouvik DassPaul EmeryMaya H BuchBenazir SaleemPublished in: Rheumatology (Oxford, England) (2021)
Non-medical switch to RTX-B was largely effective. Factors associated with RTX-B discontinuation, including comorbidities, previous biologic DMARDs, and RTX-O treatment history, may inform switch decisions. Most patients who switched back to RTX-O for LOE remained on treatment at short-term follow-up.